Acceptability and feasibility of two interventions in the MooDFOOD Trial: a food-related depression prevention randomised controlled trial in overweight adults with subsyndromal sy... by Ulrich Hegerl, Edward Watkins, Miquel Roca, Matthew Owens, Mariska Bot, Ingeborg Annemarie Brouwer, Elisabeth Kohls, Brenda Penninx, Gerard van Grootheest, Mieke Cabout, Margalida Gili, Marjolein Visser, Bep Verkerk, Nadine Paans, Carisha Thesing, Deborah Gibson-Smith, Melany Horsfall, Lena Weiss, Amy Romijn, Hannah Bunce, Owain Winfield, Harriet Bunker-Smith, Fern Durbridge, Caterina Versari Molinares, Atikah Sapar, Miquel Tortella, Clara Homar Covas, M Angeles Pérez-Ara, Adoración Castro Gracia, José Luis Reig, Jana Hoesel, Ezgi Dogan, Sabrina Baldofski, Nicole Mauche

“…We also assessed baseline determinants of adherence and assessed whether better adherence resulted in lower depressive symptoms.Design Randomised controlled trial with a 2×2 factorial design conducted between 2015 and 2017.Setting Germany, the Netherlands, UK and Spain.Participants Community sample of 1025 overweight adults with elevated depressive symptoms without a current episode of major depressive disorder. Main eligibility criteria included age (18–75 years), being overweight or obese, and having at least mild depressive symptoms, shown by a Patient Health Questionnaire Score of ≥5. …”
Get full text

Associations between social determinants of health and mental health disorders among U.S. population: a cross-sectional study by S. Tanarsuwongkul, J. Liu, M. Spaulding, K. Perea-Schmittle, M. Lohman, Q. Wang

“…Our primary outcomes were diagnoses of major depression (MD) (i.e., major depressive disorder, recurrent MD or MD in remission) and anxiety disorders (AD) (i.e., generalized AD and other anxiety-related disorders). …”
Get full text

Prevalence and factors associated with severe fatigue 2 years into the COVID-19 pandemic: a cross-sectional population-based study in Geneva, Switzerland by Silvia Stringhini, Idris Guessous, C Martinez, A Flahault, S Hurst, N Vuilleumier, L Kaiser, K M Posfay-Barbe, O Zimmermann, S Stringhini, A Uppal, P Schaller, J Berthelot, D Pittet, H Baysson, Hélène Baysson, S Yerly, E Lorthe, Mayssam Nehme, Nick Pullen, María-Eugenia Zaballa, A Bal, Clément Romain Hugo Graindorge, Stephanie Schrempft, I Arm-Vernez, A S Azman, D Bachmann, J-F Balavoine, R P Barbe, A R Bouhet, G Bryand-Rumley, F Chappuis, P Collombet, S Coudurier-Boeuf, D S Courvoisier, C de Mestral, P D’ippolito, R Dubos, R Dumont, N El Merjani, N Francioli, C Graindorge, I Guessous, S Harnal, G Kathari, O Kherad, J Lamour, P Lescuyer, A G L’Huillier, A J Loizeau, S Mechoullam, L Metral-Boffod, M Nehme, N Noël, F Pennacchio, J Perez-Saez, G Poulain, C Pugin, N Pullen, V Richard, D Rochat, S Rouzinov, K Samir, H S Ramirez, E Satin, S Schrempft, C Semaani, S Testini, D Urrutia-Rivas, C Verolet, P Vetter, J Villers, G Violot, A Wisniak, M-E Zaballa

“…Recent COVID-19 infection is substantially associated with severe fatigue, regardless of infection severity or co-occurrence of depressive disorder.Trial registration number CCER project ID 2020-00881.…”
Get full text

Meta-analysis of Therapeutic Effect in Depression Treatment of Repetitive Transcranial Magnetic Stimulation Combined Paroxetine by Xinyi GUO, Guo YU, Xiaokuo HE

“…The HAMD scores were selected as secondary outcome measure in eight articles, and Meta analysis showed that compared with the control group, pooled <italic>MD</italic> was-3.26 with 95%<italic>CI</italic> [-3.83, -2.69], <italic>Z</italic>=11.20, <italic>P</italic>&lt;0.01, in the test for overall effect, implying that the HAMD scores difference of two groups was significant in the treatment of depressive.Conclusion:The effect of repeated TMS combined Paroxetine in the treatment of first-episode depressive disorder and depression is better than Paroxetine with and without pseudo stimulus, but there is no difference in side effects. …”
Get full text

Gambaran Peningkatan Angka Kejadian Gangguan Afektif dengan Gejala Psikotik pada Pasien Rawat Inap di RSJ Prof. Dr. HB. Sa’anin Padang pada Tahun 2010 - 2011 by Aisyah Fithri Syafwan, Kurniawan Sedjahtera, Asterina .

“…<br />Keywords:manic disorder, psychotic symptoms, major depressive disorder, affective disorder mixed type</p>…”
Get full text

Should the Food and Drug Administration Limit Placebo-Controlled Trials? by Max Goodman, Connor Pedersen

“…Additionally, there is no consensus of what constitutes harm when withholding treatment; placebos are often used in trials for major depressive disorder, yet this population has statistically higher rates of self-harm and suicide without treatment compared to the general population.[14] Serious risks can be incurred due to a placebo intervention by not offering experimental treatment, without excusing the psychological harm withholding a treatment may have on a patient should it be unblinded. …”
Get full text